Related Experiment Videos
Managing atrial tachyarrhythmias in patients with implantable cardioverter defibrillators
1Department of Cardiology, University of Göttingen, Germany.
Insights
Implantable cardioverter defibrillators (ICDs) significantly improve survival but can deliver unnecessary therapy for supraventricular tachycardias (SVTs). New algorithms reduce inappropriate ICD shocks to under 5% by better distinguishing SVTs from ventricular tachycardias (VTs).
Area of Science:
- Cardiology
- Biomedical Engineering
Background:
- Implantable cardioverter defibrillators (ICDs) are crucial for preventing sudden cardiac death.
- Studies like AVID, CIDS, CASH, and MADIT confirm ICDs improve survival over antiarrhythmic drugs.
- Current ICDs primarily detect ventricular tachycardias (VTs) based on heart rate, leading to misidentification of supraventricular tachycardias (SVTs).
Purpose of the Study:
- To enhance ICD specificity in detecting ventricular tachycardias (VTs).
- To reduce unnecessary ICD therapy delivery caused by supraventricular tachycardias (SVTs).
Main Methods:
- Implementation of advanced algorithms to discriminate between VTs and SVTs.
- Utilizing programmable features and antiarrhythmic drug treatment for atrial tachyarrhythmias.
- Considering dual-chamber ICDs for specific complex arrhythmia scenarios.
Main Results:
- Enhanced detection criteria decrease unnecessary ICD therapy to less than 5% of patients.
- Atrial tachyarrhythmias can be effectively managed with current device features and treatments.
- Dual-chamber ICDs offer solutions for challenging VT/SVT discrimination cases.
Conclusions:
- Improved ICD algorithms significantly reduce inappropriate shocks from SVTs.
- Comprehensive management strategies ensure low incidence of unnecessary therapy in ICD patients.
- ICD therapy is optimized for patient safety and efficacy through advanced detection and programming.
Abstract:
The implantable cardioverter defibrillator (ICD) is accepted as the therapy of choice in preventing sudden cardiac death. Multiple studies, such as Antiarrhythmics Versus Implantable Defibrillators (AVID), the Canadian Implantable Defibrillator Study (CIDS), the Cardiac Arrest Study Hamburg (CASH), and the Multicenter Automatic Defibrillator Implantation Trial (MADIT), have shown a substantial benefit in survival rates for patients treated with ICDs compared with antiarrhythmic drug treatment. The detection of spontaneous ventricular tachycardias (VT) is based primarily on the programmed heart rate for intervention of the device. Supraventricular tachycardias (SVTs) cause unnecessary therapy delivery in about 10-20% of patients with ICDs. ICD therapy needs to be improved to become more specific for VT detection, by implementing algorithms that discriminate between VTs and SVTs. The enhanced detection criteria in currently available ICD devices are able to decrease the rate of unnecessary therapy to < 5% of patients. Atrial tachyarrhythmias can be managed with programmable features of the device, antiarrhythmic drug treatment, and in rare cases, ablation procedures. Dual-chamber ICDs, requiring an additional atrial lead, are indicated in specific situations of slow VT and concurrent, continuous SVTs at very similar heart rates. Using all these options, SVTs can be managed to achieve an acceptably low incidence of unnecessary therapy delivery in < 5% of ICD patients.